Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert
Status:
Recruiting
Trial end date:
2021-01-31
Target enrollment:
Participant gender:
Summary
Randomized, controlled treatment with an intracanalicular dexamethasone (0.4mg) insert
following cataract surgery with intraocular lens implant (IOL) combined with minimally
invasive glaucoma surgery (MIGS), specifically iStent, iStent inject or KDB in patients with
primary open angle glaucoma (POAG) or ocular hypertension (OHTN)